- ICH GCP
- Registro de ensaios clínicos dos EUA
- Ensaio Clínico NCT06678074
Estudo piloto de IC14 (Atibuclimab), um anticorpo monoclonal anti-CD14, para tratar STEMI
Estudo piloto de fase 1b de atibuclimabe (IC14) para tratamento de infarto do miocárdio com elevação do segmento ST
Adults who have had an ST-elevation myocardial infarction and were treated with stent placement will receive an intravenous infusion of a monoclonal antibody in order to prevent further heart muscle damage. The goal is to learn if this treatment improves some measures of heart function and inflammation. The study treatment patients will be compared to patients who receive placebo (inactive treatment).
Visão geral do estudo
Status
Condições
Intervenção / Tratamento
Descrição detalhada
Randomized, double-blind, placebo-controlled pilot study to evaluate the safety, exploratory efficacy, and pharmacokinetics of IC14 (atibuclimab) administered via a single IV infusion to patients with STEMI treated with percutaneous intervention. In additional to optional CCR2+ myocardial imaging, biomarkers, cardiac function and patient-reported outcome measures will be reported.
Tipo de estudo
Inscrição (Real)
Estágio
- Fase 2
- Fase 1
Contactos e Locais
Locais de estudo
-
-
Missouri
-
St Louis, Missouri, Estados Unidos, 63110
- Washington University School of Medicine
-
-
Virginia
-
Charlottesville, Virginia, Estados Unidos, 22908-1394
- University of Virginia
-
-
Critérios de participação
Critérios de elegibilidade
Idades elegíveis para estudo
Aceita Voluntários Saudáveis
Gêneros Elegíveis para o Estudo
Descrição
Inclusion Criteria:
-
Acute myocardial infarction with ST elevation at the J-point in two contiguous leads as determined by ECG.
-
TIMI grade 0 (no flow) or grade 1 (penetration without perfusion) of the culprit artery on initial coronary angiogram
-
Symptom onset prior to PCI of ≤12 hours
-
Planned to receive the local standard of care for treatment of their STEMI and follow up which must include percutaneous coronary intervention (PCI)
-
Ability to infuse study drug within 12 hours of PCI
-
Age ≥18 years, willing and able to provide written informed consent and to comply with the protocol (i.e., reporting of symptoms)
-
Capable of completing study visits
-
Females participating in the study must meet one of the following criteria:
- Postmenopausal (postmenopausal females must have no menstrual bleeding for at least 1 year);
- Surgically sterilized (e.g., hysterectomy, bilateral oophorectomy, or tubal ligation) for at least 6 months; or
- If not postmenopausal, agree to use a double method of contraception, one of which is a barrier method (e.g., intrauterine device plus condom, spermicidal gel plus condom) until 30 days after the treatment
-
Males who have not had a vasectomy must use appropriate contraception methods (barrier or abstinence) until 30 days after treatment
Exclusion Criteria:
An individual fulfilling any of the following criteria is to be excluded from enrollment in the study:
- Killip Classification for Heart Failure Class III (acute pulmonary edema) or IV (cardiogenic shock)
- Severe aortic or mitral valve disease
- Failure to reperfuse, vascular dissection, cardiac perforation, cardiac arrest, requirement for mechanical circulatory support, or acute respiratory failure requiring ventilatory support
- Major hemodynamic instability or uncontrolled ventricular arrhythmias
- Planned or conducted thrombolytic therapy for treatment of this STEMI event
- Planned or conducted coronary artery bypass graft
- Previous major vascular intervention within the last 4 weeks
- Major surgery within the last 6 weeks
- Evidence of an active gastrointestinal or urogenital bleeding
- Recent (<14 days) use of immunosuppressive or anti-inflammatory drugs (including oral corticosteroids at a prednisone equivalent dose of ≥0.5 mg/kg/day but not including inhaled or low-dose oral corticosteroids, non-steroidal anti-inflammatory drugs, or colchicine).
- Chronic inflammatory disorder (i.e., rheumatoid arthritis, systemic lupus erythematosus).
- Active infection (of any type), including chronic/recurrent infectious disease (including HBV, HCV, and HIV/AIDS), but excluding HCV+ with undetectable plasma RNA.
- Neutropenia (<1,500/mm3 or <1,000/mm3 in Black/African American patients).
- Active malignancy, excluding carcinoma in situ [any location] or localized non-melanoma skin cancer
- Participation in any study using an investigational drug or device within 30 days or within 5 half-lives of the investigational drug (whichever is longer) of entry into this study.
- Life expectancy of less than 1 year due to non-cardiac pathology
- History of allergic reaction to atibuclimab (IC14), any monoclonal antibody, or any other component used in the study (including contrast media)
- Body weight >300 pounds (weight limit of the PET/CT table)
- Known severe renal (creatinine clearance <30 mL/min) or hepatic insufficiency as well as alanine transaminase (ALT) elevation ≥ 3x upper limit of normal; isolated AST-elevation is not considered an exclusion criterion from study participation
- Any clinically significant abnormality identified at the time of Screening that in the judgment of the Investigator, or any sub-Investigator would preclude safe completion of the study
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Tratamento
- Alocação: Randomizado
- Modelo Intervencional: Atribuição Paralela
- Mascaramento: Quadruplicar
Armas e Intervenções
Grupo de Participantes / Braço |
Intervenção / Tratamento |
|---|---|
|
Experimental: Experimental drug intervention
monoclonal antibody against CD14 |
monoclonal antibody against CD14 |
|
Comparador de Placebo: Placebo
Identical-appearing normal saline for injection, intravenous, once |
sterile normal saline for injection |
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Incidence of treatment-emergent adverse events (safety and tolerability)
Prazo: Day 1-29
|
Treatment-emergent adverse events |
Day 1-29
|
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
CCR2+ cell myocardial infiltration (optional)
Prazo: 48 hours and Day 15
|
Characterization of CCR2+ cell myocardial infiltration mean standard uptake value (SUVmean) and change from 48 hours measured by myocardial PET/CT imaging at Day 15 |
48 hours and Day 15
|
|
Biomarker C-Reactive Protein
Prazo: Day 4, 15, 29
|
Change from baseline |
Day 4, 15, 29
|
|
Biomarker White Blood Cell Count
Prazo: Day 4, 15, and 29
|
Change from baseline |
Day 4, 15, and 29
|
|
Biomarker Fibrinogen
Prazo: Day 4, 15, 29
|
Change from baseline |
Day 4, 15, 29
|
|
Biomarker Interleukin 6
Prazo: Day 4, 15, and 29
|
Change from baseline |
Day 4, 15, and 29
|
|
Biomarker Interleukin-1
Prazo: Day 4, 15, and 29
|
change from baseline |
Day 4, 15, and 29
|
|
Biomarker Troponin I
Prazo: Day 4, 15, and 29
|
change from baseline |
Day 4, 15, and 29
|
|
Single-cell RNASeq
Prazo: Day 4, 15, and 29
|
change from baseline |
Day 4, 15, and 29
|
|
Cardiac death or readmission for heart failure
Prazo: Day 1-90
|
|
Day 1-90
|
|
Left Ventricular Ejection Fraction
Prazo: Day 1, Day 90
|
Change from baseline, measured by echocardiography |
Day 1, Day 90
|
|
N-terminal pro B-type natriuretic peptide
Prazo: Day 90
|
blood test measurement of heart failure |
Day 90
|
|
New York Heart Association Class
Prazo: Day 90
|
Measurement of cardiac status |
Day 90
|
|
Kansas City Cardiomyopathy Questionnaire
Prazo: Day 90
|
Patient-reported outcome measure of health status and function |
Day 90
|
Outras medidas de resultado
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Pharmacokinetic profile of serum IC14 level, including serum half life and maximum serum concentration
Prazo: baseline, 15 minutes, 6 hours, Day 4, Day 15, Day 22, Day 29
|
Serum IC14 levels |
baseline, 15 minutes, 6 hours, Day 4, Day 15, Day 22, Day 29
|
|
Pharmacodynamics
Prazo: Day 22, Day 29
|
Percent monocyte CD14 receptor occupancy |
Day 22, Day 29
|
|
Immunogenicity
Prazo: baseline, Day 29, Day 90
|
Anti-drug antibodies |
baseline, Day 29, Day 90
|
Colaboradores e Investigadores
Patrocinador
Investigadores
- Investigador principal: Marc Sintek, MD, PI
- Investigador principal: Antonio Abbate, MD, PhD, PI
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo (Real)
Conclusão Primária (Real)
Conclusão do estudo (Real)
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Real)
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Mais Informações
Termos relacionados a este estudo
Palavras-chave
Termos MeSH relevantes adicionais
Outros números de identificação do estudo
- STEMI01
Plano para dados de participantes individuais (IPD)
Planeja compartilhar dados de participantes individuais (IPD)?
Descrição do plano IPD
Included in publication supplemental materials and provided to central data base
Prazo de Compartilhamento de IPD
study completion
Critérios de acesso de compartilhamento IPD
public access through journal website and/or ClinicalTrials.gov website listing
Tipo de informação de suporte de compartilhamento de IPD
- PROTOCOLO DE ESTUDO
Informações sobre medicamentos e dispositivos, documentos de estudo
Estuda um medicamento regulamentado pela FDA dos EUA
Estuda um produto de dispositivo regulamentado pela FDA dos EUA
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .